Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Various immunodeficiencies Hyperinflammatory but inadequate immune response Clinical picture of HLH Hemophagocytic lymphohistiocytosis (HLH) Clinical symptoms and findings High fever, hepatosplenomegaly, pancytopenia Neurological symptoms, jaundice, edema, lymphadenopathy, rash High triglycerides, low fibrinogen, coagulopathy high ferritin, transaminases, bilirubin, LDH CSF pleocytosis and/or elevated protein Hemophagocytosis in BM or other organs Phagocytosing macrophages in HLH HLH Variable course of disease Rapidly progressive leading to death within weeks Transient improvements with unspecific therapies Disappearance of symptoms without therapy Disappearance of symptoms with immunosuppressive/immunomodulatory drugs HLH Classification Genetic, primary HLH Acquired, secondary HLH FHLH - Perforin mutations (chr.10) - Chromosom 9 linkage - Unknown mutations Exogenous agents - infectious organisms, toxins (VAHS, IAHS) HLH - Immune deficiencies CHS Griscelli syndrome XLP SCID Endogenous products - tissue damage - radical stress - metabolic products Rheumatic disorders Malignancies GJ 2002 Leishmaniase „IAHS“ in Childhood (219 cases from the literature) 1979-1995 Organism Clinical outcome Dead Alive No data 121 72 27 22 Other viruses 28 11 13 4 Bacteria 11 2 9 0 2 1 1 0 1 57 0 13 1 33 0 11 EB Virus Fungi Protozoae No organism „IAHS“ in Childhood (219 cases from the literature) (1979-1995) Age Clinical outcome Dead Alive No data < 3 years: 77 40 26 11 > 3 years: 82 29 47 6 „Children“: 60 60 22 4 103/198 95/198 (52%) (48%) Total 219 HLH Diagnostic criteria Histiocyte Society 1991 Clinical Fever > 38.5 Splenomegaly Laboratory Cytopenia of => 2/3 cell lines Hypertriglyceridemia and/or hypofibrinogenemia Histopathology Hemophagocytosis in bone marrow or spleen or liver or lymphnode Strong supportive evidence are spinal fluid pleocytosis, liver histology resembling chronic persistent hepatitis, low natural killer cell activity Diagnostic criteria Fever Splenomegaly Cytopenia 3 cell lines Cytopenia 2 cell lines Cytopenia 1 cell line Hb < 90 g/l Thrombocytes < 100/nl Neutrophils < 1.0/nl Hemophagocytosis NK cell activity negative or decreased sCD 25 > 5000 U/ml Fibrinogen < 1,5 g/l Triglycerides fasting >= 2mmol/l LDH > 400 U/l GOT > 50 U/l GPT > 50 U/l Natrium < 130 mmol/l CNS cells >=5/ul CNS protein 0 20 40 60 80 100 Percent of cases At initial presentation At diagnosis HLH Immunological parameters Hypercytokinemia (TNF, INF, IL 6, IL 8, IL 10), Increased soluble CD 25 (interleukin 2 receptor -chain) Increased soluble CD95-ligand NK-cell activity below 5% lysis CD2/CD86 positive cells in lymphocyte gate Phagocytosing dendritic cells in culture HLH Therapy Cytostatic and immunsuppressive/ immunomodulatory drugs: Corticosteroids, Cyclosporin A, Etoposide Immunoglobulins, Antithymocyte globulin Bone marrow transplantation Prognosis In 20% no response to therapy After BMT 60-70% relapse-free survival